These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35956400)

  • 1. Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease.
    Naseri K; Saadati S; Yari Z; Askari B; Mafi D; Hoseinian P; Asbaghi O; Hekmatdoost A; de Courten B
    Nutrients; 2022 Aug; 14(15):. PubMed ID: 35956400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population.
    Lin IT; Lee MY; Wang CW; Wu DW; Chen SC
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33498329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease.
    Sheng G; Lu S; Xie Q; Peng N; Kuang M; Zou Y
    Lipids Health Dis; 2021 Oct; 20(1):134. PubMed ID: 34629059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between healthy eating index-2015 with anthropometric, cardiometabolic and hepatic indices among patients with non-alcoholic fatty liver disease.
    Hosseini SA; Shayesteh AA; Hashemi SJ; Rahimi Z; Saki N; Bavi Behbahani H; Cheraghian B; Alipour M
    BMC Gastroenterol; 2024 May; 24(1):159. PubMed ID: 38724894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatty liver biomarkers and insulin resistance indices in the prediction of non-alcoholic fatty liver disease in Ghanaian patients.
    Bockarie AS; Nartey YA; Nsiah P; Edzie EKM; Tuoyire D; Acquah S; Eliason S; Nkum B
    Endocrinol Diabetes Metab; 2023 Nov; 6(6):e456. PubMed ID: 37814510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents.
    Chin J; Mori TA; Adams LA; Beilin LJ; Huang RC; Olynyk JK; Ayonrinde OT
    JHEP Rep; 2020 Dec; 2(6):100150. PubMed ID: 32984791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
    Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
    Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus.
    Malek M; Khamseh ME; Chehrehgosha H; Nobarani S; Alaei-Shahmiri F
    Endocrine; 2021 Dec; 74(3):538-545. PubMed ID: 34355342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes.
    Li N; Tan H; Xie A; Li C; Fu X; Xang W; Kirim A; Huang X
    BMC Endocr Disord; 2022 Apr; 22(1):101. PubMed ID: 35428219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease.
    Ristic-Medic D; Kovacic M; Takic M; Arsic A; Petrovic S; Paunovic M; Jovicic M; Vucic V
    Nutrients; 2020 Dec; 13(1):. PubMed ID: 33374554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Deregulations in Patients with Polycystic Ovary Syndrome.
    Jabczyk M; Nowak J; Jagielski P; Hudzik B; Kulik-Kupka K; Włodarczyk A; Lar K; Zubelewicz-Szkodzińska B
    Metabolites; 2023 Feb; 13(2):. PubMed ID: 36837921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease.
    Cen C; Wang W; Yu S; Tang X; Liu J; Liu Y; Zhou L; Yu J; Zheng S
    Hepatol Int; 2020 Sep; 14(5):808-816. PubMed ID: 32572817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease.
    Gelli C; Tarocchi M; Abenavoli L; Di Renzo L; Galli A; De Lorenzo A
    World J Gastroenterol; 2017 May; 23(17):3150-3162. PubMed ID: 28533672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Six Insulin Resistance Surrogates and Nonalcoholic Fatty Liver Disease Among Older Adults: A Cross-Sectional Study.
    Li H; Shi Z; Chen X; Wang J; Ding J; Geng S; Sheng X; Shi S
    Diabetes Metab Syndr Obes; 2023; 16():1685-1696. PubMed ID: 37309507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Hepatic Steatosis Index and Fatty Liver Index with Carotid Atherosclerosis in Type 2 Diabetes.
    Wang C; Cai Z; Deng X; Li H; Zhao Z; Guo C; Zhang P; Li L; Gu T; Yang L; Zhao L; Wang D; Yuan G
    Int J Med Sci; 2021; 18(14):3280-3289. PubMed ID: 34400897
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications.
    Bullón-Vela V; Abete I; Tur JA; Konieczna J; Romaguera D; Pintó X; Corbella E; Martínez-González MA; Sayón-Orea C; Toledo E; Corella D; Macías-Gonzalez M; Tinahones FJ; Fitó M; Estruch R; Ros E; Salas-Salvadó J; Daimiel L; Mascaró CM; Zulet MA; Martínez JA
    Ther Adv Endocrinol Metab; 2020; 11():2042018820958298. PubMed ID: 33149882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.
    Rahmani S; Asgary S; Askari G; Keshvari M; Hatamipour M; Feizi A; Sahebkar A
    Phytother Res; 2016 Sep; 30(9):1540-8. PubMed ID: 27270872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial.
    Ali Sangouni A; Abdollahi S; Mozaffari-Khosravi H
    BMC Cardiovasc Disord; 2022 May; 22(1):212. PubMed ID: 35538431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the cardiometabolic profiles of adolescents conceived through ART with those of a non-ART cohort.
    Wijs LA; Doherty DA; Keelan JA; Burton P; Yovich JL; Beilin L; Mori TA; Huang RC; Adams LA; Olynyk JK; Ayonrinde OT; Penova-Veselinovic B; Hart RJ
    Hum Reprod; 2022 Jul; 37(8):1880-1895. PubMed ID: 35640037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.